Component
Rat P-glycoprotein transporter family
Study-scoped entity; inspect species, exposure, model and limitations on each claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
Where it participates (unsigned role)
EGCG pretreatment reduced the specified transporter mRNA by a reported 2.61-fold.
Experimental context and source evidence
- experimental_model
- Male spontaneously hypertensive rats; EGCG 10 mg/kg/day for 14 days and nadolol 10 mg/kg on day 14.
- limitations
- Rat transcription/exposure results; mRNA changes do not establish transporter protein activity or a human effect size.
- nutrient_topic
- EGCG collection; comparator and shared-pathway records retain their actual intervention. · Epigallocatechin-3-gallate (EGCG)
- plain_language
- The study measured a transporter-expression change.
- primary_references
- Oral epigallocatechin gallate reduces intestinal nadolol absorption via modulation of Oatp1a5 and Oct1 transcriptional levels in spontaneously hypertensive rats. · 2021 · https://pubmed.ncbi.nlm.nih.gov/34303263/ · DOI 10.1016/j.phymed.2021.153623
EGCG: receptor signaling, metabolism, nutrient interactions and discovery questions (2026-09-18) · lines 532–538
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Male spontaneously hypertensive rats; EGCG 10 mg/kg/day for 14 days and nadolol 10 mg/kg on day 14. · source_derived_draft · unverified_draft
## egcg-hepatic-pgp The study measured a transporter-expression change. EGCG pretreatment reduced the specified transporter mRNA by a reported 2.61-fold. Model: Male spontaneously hypertensive rats; EGCG 10 mg/kg/day for 14 days and nadolol 10 mg/kg on day 14. Limitations: Rat transcription/exposure results; mRNA changes do not establish transporter protein activity or a human effect size. Evidence access: primary abstract. Oral epigallocatechin gallate reduces intestinal nadolol absorption via modulation of Oatp1a5 and Oct1 transcriptional levels in spontaneously hypertensive rats. · 2021 · https://pubmed.ncbi.nlm.nih.gov/34303263/ · DOI 10.1016/j.phymed.2021.153623
Complete structured claim and evidenceEGCG pretreatment reduced the specified transporter mRNA by a reported 8.01-fold.
Experimental context and source evidence
- experimental_model
- Male spontaneously hypertensive rats; EGCG 10 mg/kg/day for 14 days and nadolol 10 mg/kg on day 14.
- limitations
- Rat transcription/exposure results; mRNA changes do not establish transporter protein activity or a human effect size.
- nutrient_topic
- EGCG collection; comparator and shared-pathway records retain their actual intervention. · Epigallocatechin-3-gallate (EGCG)
- plain_language
- The study measured a transporter-expression change.
- primary_references
- Oral epigallocatechin gallate reduces intestinal nadolol absorption via modulation of Oatp1a5 and Oct1 transcriptional levels in spontaneously hypertensive rats. · 2021 · https://pubmed.ncbi.nlm.nih.gov/34303263/ · DOI 10.1016/j.phymed.2021.153623
EGCG: receptor signaling, metabolism, nutrient interactions and discovery questions (2026-09-18) · lines 516–522
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Male spontaneously hypertensive rats; EGCG 10 mg/kg/day for 14 days and nadolol 10 mg/kg on day 14. · source_derived_draft · unverified_draft
## egcg-ileal-pgp The study measured a transporter-expression change. EGCG pretreatment reduced the specified transporter mRNA by a reported 8.01-fold. Model: Male spontaneously hypertensive rats; EGCG 10 mg/kg/day for 14 days and nadolol 10 mg/kg on day 14. Limitations: Rat transcription/exposure results; mRNA changes do not establish transporter protein activity or a human effect size. Evidence access: primary abstract. Oral epigallocatechin gallate reduces intestinal nadolol absorption via modulation of Oatp1a5 and Oct1 transcriptional levels in spontaneously hypertensive rats. · 2021 · https://pubmed.ncbi.nlm.nih.gov/34303263/ · DOI 10.1016/j.phymed.2021.153623
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.